科研之友
微信
新浪微博
Facebook
分享链接
摘要
This randomized-double-blind aimed to show the effect of middle dose of topiramate and monitor the sodium valproate as a treatment quite acceptable in migraine prophylaxis as well as compare health and treatment effects in reducing both frequency and the severity of headache. Seventy-three females patients filled questionnaire based on the migraine disability assessment score (MIDAS) in the beginning and end of the study. Frequency, severity, duration of headache attacks and symptoms of drug in each of the patients are listed in his file. The effects of middle dose of topiramate (50-75 mg) and sodium valproate (400-600 mg) in the prevention of migraine headache was compared. Out of the 73 patients three cases were excluded due to unwanted and adverse events. Although, both drugs have been successful in reducing headache frequency more than 50% within the study, but there was no significant difference. The MIDAS score in topiramate group reduced more than the group receiving valproate sodium, which indicates changes, was statistically significant in both groups before treatment. The most common complications recorded in the group receiving topiramate were, paresthesia followed by weight loss, drowsiness and dizziness in topiramate group. While, the most common complications recorded in the group receiving sodium valproate were, drowsiness, weight gain, hair loss, nausea and Tremor. This trial demonstrates that topiramate significantly reduced mean monthly migraine and was a safe and well-tolerated preventive therapy in this group of subjects with migraine, a therapeutic area in which profound clinical needs exist.
- 出版日期2010-10
